Drug details:
Molecular formula: C₁₁H₁₁F₃N₂O

Standard name: 3-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol

Synonyms:

3-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol 3-[5-(trifluoromethyl)-1h-benzo[d]imidazol-2-yl]propan-1-ol 2-(3-Hydroxy-N-Propyl)-5-(Trifluoromethyl)-Benzimidazole 2-(3-hydroxy-1-propyl)-5-(trifluoromethyl)benzimidazole 2-(3-hydroxypropyl)-5-(trifluoromethyl)benzimidazole 3-[5-(trifluoromethyl)-1H-1,3-benzodiazol-2-yl]propan-1-ol 2-(3-hydroxypropyl)-5-(trifluoromethyl)-1h-benzimidazole 1H-Benzimidazole-2-propanol, 6-(trifluoromethyl)- 3-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)propan-1-ol ......

Curated SMILES: OCCCC1=NC2=CC=C(C(F)(F)F)C=C2N1

Evidence for compound's anti-virulence activity:

Vibrio
Related VFcategory: Post-translational modification
Target: DsbA
Drug effect: Binds to the hydrophobic groove of oxidized DsbA enzymes involved in the functional folding and secretion of virulence factors, including CT and TCP.
Max phase: Preclinical (in vitro)
Publication:
Wang G, et al., 2022. Selective Binding of Small Molecules to Vibrio cholerae DsbA Offers a Starting Point for the Design of Novel Antibacterials. ChemMedChem 17(6):e202100673.